Extending a past Type 1 diabetes immune study
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study is for people who already took part in an earlier immune-tolerance program for Type 1 diabetes. It tests whether continuing follow-up and assessments can be done safely and may help learn more about long-term immune effects of treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You previously participated in an Immune Tolerance Network (ITN) Type 1 diabetes study that was approved by the executive committee.
- You (or your child, if applicable) can sign the study consent/assent forms.
- Your doctor believes you can take part safely without other health problems getting in the way.
- You can realistically attend study visits on the required schedule.
- You can complete the required study tests and check-ins each time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows children who are at genetic risk for type 1 diabetes or have early immune signs (autoantibodies) but do not yet need insulin. It provides extra checkups and information to catch the disease early and help families understand their child's risk.
This early-stage trial tests a combination approach to help your immune system stop attacking insulin-producing cells in newly diagnosed type 1 diabetes. It aims to preserve your body's ability to make insulin and slow disease progression.
This study tests a new treatment called GNTI-122 for adults recently diagnosed with type 1 diabetes who still make some insulin. It aims to see if the treatment can help protect the cells that produce insulin.
This trial compares two medicines, teplizumab and ATG, to see if they can delay or prevent type 1 diabetes from progressing to needing insulin. It is for people ages 4 to 35 who have early signs of diabetes (stage 2) and specific autoantibodies.
This trial tests whether giving your own regulatory T cells (a type of immune cell) back to you can help slow or stop the immune attack on your pancreas in type 1 diabetes. It is for people aged 8 to 65 who still make some insulin.
This study tests two different medications (Anti-Thymocyte Globulin and Adalimumab or Verapamil) to see if they can slow down the loss of insulin production in people with newly diagnosed type 1 diabetes. Participants will be randomly assigned to receive one of the treatments and will be followed for about a year to see how well their bodies still make insulin.
Hear when a new T1D trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.